Global Ankylosing Spondylitis Market 2015-2019

強直性脊椎炎(Ankylosing Spondylitis)治療薬の世界市場2015-2019

◆タイトル:Global Ankylosing Spondylitis Market 2015-2019
◆商品コード:IRTNTR5050
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年1月7日
◆ページ数:102
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Five UserUSD3,300 ⇒換算¥363,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、強直性脊椎炎(Ankylosing Spondylitis)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、強直性脊椎炎(Ankylosing Spondylitis)治療薬の世界市場規模及び予測、種類別分析、作用機序別分析、投与経路(ROA)別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Ankylosing Spondylitis
Ankylosing spondylitis is a subtype of spondylarthropathy. The primary symptoms of the disease are inflammatory spinal pain with subsequent limitation of spine mobility and chest expansion. Ankylosing spondylitis can be diagnosed using clinical signs, radiological signs (sacroiliitis) and the presence of HLA-B27 antigen. According to the NIH and NIAMS, ankylosing spondylitis is a type of arthritis, which affects the joints in the vertebral column severely. It is a progressive inflammatory disease that typically becomes evident during early to mid-adulthood, as per NORD. It can also lead to the loss of spinal mobility for the affected individuals. The cause of the disease is not known, however, the HLA-B27 gene plays a major role. Ankylosing spondylitis is hereditary in nature.

TechNavio’s analysts forecast the Global Ankylosing Spondylitis market to grow at a CAGR of 5.05 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Ankylosing Spondylitis market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of ankylosing spondylitis. The market is segmented based on the mechanism of action of the drugs used to treat ankylosing spondylitis as illustrated below:
• TNF Inhibitors
• COX Inhibitors
• Others

On the type of molecule used for the treatment of ankylosing spondylitis, as illustrated below:
• Biologics
• Small Molecules

On the basis of route of administration adopted for the treatment of ankylosing spondylitis, the Global Ankylosing Spondylitis market is segmented as follows:
• Oral
• Parenteral

In addition, the market is also bifurcated on the basis of dosage forms of the drugs used in the treatment of the disease:
• Solid
• Liquid

The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. Also, the late-stage pipeline molecules developed for the treatment of Ankylosing Spondylitis have been discussed.

TechNavio’s report, Global Ankylosing Spondylitis Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC region and the EMEA; it also covers the Global Ankylosing Spondylitis market landscape and its growth prospects in the coming years. The report also includes a discussion on the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Abbvie
• Amgen
• Janssen Pharmaceuticals
• Merck & Co.
• Pfizer

[Other Prominent Vendors]
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celgene
• Celltrion
• Eisai
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Novartis
• Otsuka Pharmaceutical
• Regeneron Pharmaceuticals
• Sanofi
• Shanghai Pharmaceuticals
• UCB

[Market Driver]
• Presence of Unmet Need
• For a full, detailed list, view our report

[Market Challenge]
• Threat from Patent Expiry
• For a full, detailed list, view our report

[Market Trend]
• Market Dominance by Biologics
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Disease Overview
06.1 Understanding the Disease
06.2 Causes of Ankylosing Spondylitis
06.3 Pathophysiology
06.4 Epidemiology
06.5 Diagnosis
06.6 Treatment and Management
06.6.1 Analgesics
06.6.2 Corticosteroids
06.6.3 DMARDs
06.6.4 Biologics
06.6.5 Physiotherapy
06.6.6 Surgery
06.7 Economic Burden

07.Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis

08.Market Segmentation by Mechanism of Action
08.1 TNF Inhibitors
08.2 COX Inhibitors
08.3 Others

09.Market Segmentation by Type of Molecule
09.1 Biologics
09.2 Small Molecules

10.Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral

11.Market Segmentation by Dosage Forms
11.1 Solid
11.2 Liquid

12.Geographical Segmentation

13.Buying Criteria

14.Market Growth Drivers

15.Drivers and their Impact

16.Market Challenges

17.Impact of Drivers and Challenges

18.Market Trends

19.Trends and their Impact

20.Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Competitive Assessment of the Top Drugs for Ankylosing Spondylitis
20.2.2 Abbvie
20.2.3 Janssen Pharmaceuticals
20.2.4 Amgen
20.2.5 Pfizer
20.2.6 Merck
20.3 Other and Future Prominent Vendors

21.Pipeline Portfolio

22.Key Vendor Analysis
22.1 AbbVie Inc.
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Product Segmentation by Revenue 2013
22.1.4 Product Segmentation by Revenue 2012 and 2013
22.1.5 Sales by Geography
22.1.6 Business Strategy
22.1.7 Key Developments
22.1.8 SWOT Analysis
22.2 Amgen
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation by Revenue 2013
22.2.4 Product Portfolio by Revenue 2013
22.2.5 Business Segmentation by Revenue 2012 and 2013
22.2.6 Geographical Segmentation by Revenue 2013
22.2.7 Business Strategy
22.2.8 Recent Developments
22.2.9 SWOT Analysis
22.3 Janssen Pharmaceuticals
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Recent Developments
22.3.4 SWOT Analysis
22.4 Merck
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation by Revenue 2013
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Sales by Geography
22.4.6 Business Strategy
22.4.7 Key Developments
22.4.8 SWOT Analysis
22.5 Pfizer
22.5.1 Key Facts
22.5.2 Business Overview
22.5.3 Business Segmentation by Revenue 2013
22.5.4 Business Segmentation by Revenue 2012 and 2013
22.5.5 Geographical Segmentation by Revenue
22.5.6 Business Strategy
22.5.7 Key Developments
22.5.8 SWOT Analysis

23.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Executive Summary of Global Ankylosing Spondylitis Market 2014-2019
Exhibit 3: Snapshot of Ankylosing Spondylitis
Exhibit 4: Diagnosis of Ankylosing Spondylitis
Exhibit 5: Treatment and Management of Ankylosing Spondylitis
Exhibit 6: Snapshot of the Economic Burden of Ankylosing Spondylitis
Exhibit 7: Snapshot of the Global Ankylosing Spondylitis Market
Exhibit 8: Global Ankylosing Spondylitis Market 2014-2019 (US$ million)
Exhibit 9: Drivers and Challenges of Global Ankylosing Spondylitis Market
Exhibit 10: Global Ankylosing Spondylitis Market Segmentation by Mechanism of Action
Exhibit 11: Global Ankylosing Spondylitis Market Segmentation by Mechanism of Action 2014
Exhibit 12: Global Ankylosing Spondylitis Market Segmentation by Type of Molecule
Exhibit 13: Global Ankylosing Spondylitis Market Segmentation by Type of Molecule 2014
Exhibit 14: Global Ankylosing Spondylitis Market Segmentation by Route of Administration
Exhibit 15: Global Ankylosing Spondylitis Market Segmentation by Route of Administration 2014
Exhibit 16: Global Ankylosing Spondylitis Market Segmentation by Dosage Forms
Exhibit 17: Global Ankylosing Spondylitis Market Segmentation by Dosage Forms 2014
Exhibit 18: Global Ankylosing Spondylitis Market by Geographical Segmentation 2014
Exhibit 19: Buying Criteria of the Global Ankylosing Spondylitis Market
Exhibit 20: Drivers and their Impact on the Key Customer Category of the Global Ankylosing Spondylitis Market
Exhibit 21: Drivers and Their Geography-wise Impact on the Global Ankylosing Spondylitis Market
Exhibit 22: YoY Sales Comparison of Top Drugs used for Ankylosing Spondylitis 2010-2013 (US$ million)
Exhibit 23: Revenue Share of the Top Drugs used for Ankylosing Spondylitis 2010-2013
Exhibit 24: Abbvie: Product Portfolio for Ankylosing Spondylitis
Exhibit 25: YoY Global Sales of Humira 2008-2013 (US$ million)
Exhibit 26: Janssen: Product Portfolio for Ankylosing Spondylitis
Exhibit 27: YoY Sales of Remicade 2005-2013 (US$ million)
Exhibit 28: YoY Sales of Simponi 2010-2013 (US$ million)
Exhibit 29: Amgen: Product Portfolio for Ankylosing Spondylitis
Exhibit 30: YoY Sales of Enbrel (In US and Canada) 2005-2013 (US$ million)
Exhibit 31: YoY Sales of Enbrel In US 2005-2013 (US$ million)
Exhibit 32: YoY Sales of Enbrel In Canada 2005-2013 (US$ million)
Exhibit 33: Region-wise Sales Comparison of Enbrel 2005-2013 (US$ million)
Exhibit 34: Pfizer: Product Portfolio for Ankylosing Spondylitis
Exhibit 35: YoY Sales of Enbrel (Outside US and Canada) 2009-2013 (US$ million)
Exhibit 36: YoY Sales of Enbrel (Outside US and Canada) 2008-2013 (US$ million)
Exhibit 37: Merck: Product Portfolio for Ankylosing Spondylitis
Exhibit 38: YoY Sales of Remicade 2005-2013 (US$ million)
Exhibit 39: YoY Sales of Simponi 2010-2013 (US$ million)
Exhibit 40: AbbVie Inc.: Product Segmentation by Revenue 2013
Exhibit 41: AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 42: AbbVie Inc.: Sales by Geography 2013
Exhibit 43: Amgen: Business Segmentation by Revenue 2013
Exhibit 44: Amgen: Product Portfolio by Revenue 2013
Exhibit 45: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 46: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 47: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 48: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 49: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 50: Pfizer: Business Segmentation by Revenue 2013
Exhibit 51: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 52: Pfizer: Geographical Segmentation by Revenue 2013



【掲載企業】

Abbvie , Amgen , Janssen Pharmaceuticals , Merck & Co. , Pfizer , Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eisai, F. Hoffmann-La Roche, Merck Sharp & Dohme, Novartis, Otsuka Pharmaceutical, Regeneron Pharmaceuticals, Sanofi, ShanghaiPharmaceuticals, UCB

【資料のキーワード】

強直性脊椎炎、治療薬、製薬、作用機序

★調査レポート[強直性脊椎炎(Ankylosing Spondylitis)治療薬の世界市場2015-2019] (Global Ankylosing Spondylitis Market 2015-2019 / IRTNTR5050)販売に関する免責事項
[強直性脊椎炎(Ankylosing Spondylitis)治療薬の世界市場2015-2019] (Global Ankylosing Spondylitis Market 2015-2019 / IRTNTR5050)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆